Search Results - "Gennusa, Vincenzo"

BRCA -associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? by Fanale, Daniele, Corsini, Lidia Rita, Brando, Chiara, Randazzo, Ugo, Bono, Marco, Pedone, Erika, Perez, Alessandro, Sciacchitano, Roberta, Cancelliere, Daniela, Piraino, Paola, Giurintano, Ambra, Bazan Russo, Tancredi Didier, Ferraro, Pietro, Rinaldi, Gaetana, Spinnato, Valeria, Gennusa, Vincenzo, Pernice, Gianfranco, Vieni, Salvatore, Pantuso, Gianni, Russo, Antonio, Bazan, Viviana

“…Although hereditary male neoplasms are quite rare, individuals harbouring germline pathogenic variants (PVs) may have a risk of developing tumours associated…”
Get full text

Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints by Fanale, Daniele, Corsini, Lidia Rita, Bono, Marco, Randazzo, Ugo, Barraco, Nadia, Brando, Chiara, Cancelliere, Daniela, Contino, Silvia, Giurintano, Ambra, Magrin, Luigi, Pedone, Erika, Perez, Alessandro, Piraino, Paola, Pivetti, Alessia, Giovanni, Emilia Di, Russo, Tancredi Didier Bazan, Prestifilippo, Ornella, Gennusa, Vincenzo, Pantuso, Gianni, Russo, Antonio, Bazan, Viviana

“…Specific tumor-derived extracellular vesicles, called exosomes, are considered as potential key players in cross-talk between immune system and tumor…”
Get full text

Efficacy and safety of docetaxel (D) vs androgen-receptor signaling inhibitors (ARSi) as second-line therapy (Rx) after progression on alternative ARSi as first-line Rx for patients who are elderly (≥75 years old) with metastatic castration-resistant prostate cancer (mCRPC) in a multicenter international database: A SPARTACUSS–Meet-URO 26 study by Gennusa, Vincenzo, Saieva, Calogero, Lee-Ying, Richard M., Nuzzo, Pier Vitale, Spinelli, Gian Paolo, Zanardi, Elisa, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana Bueno, Patrikidou, Anna, Andrade, Livia, Pereira Mestre, Ricardo, Fornarini, Giuseppe, Procopio, Giuseppe, Santini, Daniele, Sweeney, Christopher, Heng, Daniel Yick Chin, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo

“…166 Background: About 2/3 of all prostate cancer (PCa) deaths occur in patients aged ≥75, who are frequently diagnosed with advanced PCa. ARSi abiraterone…”
Get full text

Docetaxel Versus Androgen-Receptor Signaling Inhibitors (ARSI) as Second-Line Therapy After Failure of First-Line Alternative ARSI for the Elderly ≥ 75 Years Old With Metastatic Castration-Resistant Prostate Cancer (mCRPC): A SPARTACUSS—Meet-URO 26 Real-World Study by Patrikidou, Anna, Saieva, Calogero, Lee-Ying, Richard, Nuzzo, Pier Vitale, Zarif, Talal El, McClure, Heather, Davidsohn, Matthew, Eid, Marc, Spinelli, Gian Paolo, Catalano, Fabio, Cremante, Malvina, Fotia, Giuseppe, Rossetti, Sabrina, Valenca, Loana, Vauchier, Charles, Ottanelli, Carlotta, Andrade, Livia, Gennusa, Vincenzo, Mestre, Ricardo Pereira, Fornarini, Giuseppe, Pignata, Sandro, Procopio, Giuseppe, Santini, Daniele, Ravi, Praful, Sweeney, Christopher, Heng, Daniel, De Giorgi, Ugo, Fizazi, Karim, Russo, Antonio, Francini, Edoardo

“…Androgen receptor signalling inhibitors (ARSIs) abiraterone acetate (AA) enzalutamide (Enza), are currently the standard first-line (L1) treatments for…”
Get full text

Linking patterns and processes across scales: the application of scale-transition theory to algal dynamics on rocky shores by Benedetti-Cecchi, Lisandro, Tamburello, Laura, Bulleri, Fabio, Maggi, Elena, Gennusa, Vincenzo, Miller, Matthew

“…Understanding how species and environments respond to global anthropogenic disturbances is one of the greatest challenges for contemporary ecology. The ability…”
Get full text